Eli Lilly and Co (Eli Lilly and Co) Debt-to-Equity

: 2.34 (As of Dec. 2023)

View and export this data going back to 1970. Start your Free Trial

Eli Lilly and Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6,905 Mil. Eli Lilly and Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18,321 Mil. Eli Lilly and Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $10,772 Mil. Eli Lilly and Co's debt to equity for the quarter that ended in Dec. 2023 was 2.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eli Lilly and Co's Debt-to-Equity or its related term are showing as below:

LLY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.52 Med: 1.35 Max: 5.88
Current: 2.34

During the past 13 years, the highest Debt-to-Equity Ratio of Eli Lilly and Co was 5.88. The lowest was 0.52. And the median was 1.35.

LLY's Debt-to-Equity is ranked worse than
96.14% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.285 vs LLY: 2.34

Eli Lilly and Co Debt-to-Equity Historical Data

The historical data trend for Eli Lilly and Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

5.88

2.94

1.88

1.53

2.34

Eli Lilly and Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.53	1.69	1.70	1.80	2.34

Competitive Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eli Lilly and Co Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Debt-to-Equity falls into.

Eli Lilly and Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eli Lilly and Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6904.5	+	18320.8)	/	10771.9
	=	2.34

Eli Lilly and Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6904.5	+	18320.8)	/	10771.9
	=	2.34

Eli Lilly and Co (NYSE:LLY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eli Lilly and Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co (Eli Lilly and Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

LLY:Mexico 1LLY:Italy LLY:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Switzerland LLY:Canada LILY34:Brazil LLYC:Austria LLY:Argentina

Address

Lilly Corporate Center, Indianapolis, IN, USA, 46285

Website

https://www.lilly.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Executives

Lilly Endowment Inc	10 percent owner	2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski	officer: Chief Accounting Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems	officer: SVP, ERM & CECO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson	officer: SVP and Pres., Lilly Bio-Meds	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White	officer: SVP & Pres-Lilly Oncology	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier	officer: EVP, HR & Diversity	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai	director
Mary Lynne Hedley	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van	officer: SVP, CEO LoxoONC, Pres LlyONC	C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau	officer: SVP & CIDO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez	officer: SVP & Pres., Mfg. Operations	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson	director	C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi	officer: SVP & CFO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger	director	450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017